(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 3.94% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.43%.
Surmodics's revenue in 2025 is $121,575,000.On average, 2 Wall Street analysts forecast SRDX's revenue for 2025 to be $1,773,251,977, with the lowest SRDX revenue forecast at $1,749,086,217, and the highest SRDX revenue forecast at $1,797,417,736. On average, 2 Wall Street analysts forecast SRDX's revenue for 2026 to be $1,867,555,636, with the lowest SRDX revenue forecast at $1,835,310,791, and the highest SRDX revenue forecast at $1,899,800,481.
In 2027, SRDX is forecast to generate $1,993,103,191 in revenue, with the lowest revenue forecast at $1,940,267,404 and the highest revenue forecast at $2,045,938,979.